TG Therapeutics (TGTX) Raised Revenue Guidance After Q2, Is It Still Below Fair Value?
TG Therapeutics (TGTX) reported Q2 2026 results with higher revenue and lower net income, and raised full-year revenue guidance to about $950 million, according to the company. The stock last traded at $47.94, framed by Simply Wall St as modestly undervalued versus a $51.71 fair value, largely tied to BRIUMVI ramp-up and market access.
How this was made
The 30-second read
Why it matters
The guidance raise is the actionable catalyst in the text, but the article emphasizes that the valuation case remains sensitive to BRIUMVI competitive and pricing dynamics.
Market read
Traders may reassess near-term expectations after the guidance lift, while monitoring whether BRIUMVI execution can justify the remaining valuation discount.
What to watch
Lower net income alongside higher revenue guidance could signal cost pressure or timing of expenses; without details, traders should scrutinize margin trajectory and cash burn implications.
Background
Simply Wall St discusses TG Therapeutics’ Q2 2026 results, a full-year revenue guidance lift, and a valuation narrative centered on BRIUMVI’s ramp.
Ticker impact
TG Therapeutics lifted full-year revenue guidance to about $950 million after Q2 results, keeping BRIUMVI ramp expectations central to the valuation.
Near-term bias modestly positive, with volatility tied to how investors underwrite BRIUMVI ramp versus any competitive or pricing pushback.
The text provides a specific guidance level and links the valuation thesis to BRIUMVI ramp; however, it does not add detailed new clinical, regulatory, or financial datapoints beyond the guidance update.
Market effects
Reinforces investor focus on commercial-stage biotech revenue durability and product ramp execution, especially for subcutaneous oncology/hematology launches.
Limited regional spillover implied; story is company-specific within US biotech.
Primarily US-focused, but BRIUMVI market access expansion could matter for broader investor sentiment toward similar global launch stories.
Counterpoint
The article’s “undervalued” framing may be overly dependent on BRIUMVI ramp assumptions; if uptake or pricing disappoints, the guidance raise may not close the valuation gap.
Key entities
- companyTG Therapeutics
Commercial-stage biopharmaceutical company; subject of the article’s guidance and valuation discussion.
- productBRIUMVI
TG Therapeutics’ therapy whose subcutaneous launch and market access expansion are cited as the main driver of future revenue growth.
